



OPEN ACCESS

EDITED AND REVIEWED BY
Wolfram Weckwerth,
University of Vienna, Austria

*CORRESPONDENCE
Alessandra Sussulini,
sussulini@unicamp.br

SPECIALTY SECTION
This article was submitted to
Metabolomics,
a section of the journal
Frontiers in Molecular Biosciences

RECEIVED 14 July 2022
ACCEPTED 17 November 2022
PUBLISHED 24 November 2022

CITATION
Sussulini A, Xia J and Orešič M (2022),
Editorial: Multi-omics: Trends and
applications in clinical research.
Front. Mol. Biosci. 9:994239.
doi: 10.3389/fmolb.2022.994239

COPYRIGHT
© 2022 Sussulini, Xia and Orešič. This is
an open-access article distributed
under the terms of the [Creative
Commons Attribution License \(CC BY\)](#).
The use, distribution or reproduction in
other forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution
or reproduction is permitted which does
not comply with these terms.

Editorial: Multi-omics: Trends and applications in clinical research

Alessandra Sussulini^{1*}, Jianguo Xia² and Matej Orešič³

¹State University of Campinas, Campinas, Brazil, ²McGill University, Montreal, QC, Canada, ³Örebro University, Örebro, Sweden

KEYWORDS

multi-omics, metabolomics, proteomics, data integration, transcriptomics

Editorial on the Research Topic

[Multi-omics: Trends and applications in clinical research](#)

Omics-based studies have substantially contributed to the emergence and progress of systems biology over the past decades. Each layer of omics data provides a unique perspective on the biological system at a particular molecular level (e.g., RNA, proteins, metabolites), with all levels being involved in different yet inter-related biological processes. However, data at any individual omics level cannot fully explain how these different multi-layered biological processes interact and how they lead to emergence of complex phenotypes. To answer these questions, multi-omics strategies have been increasingly employed to obtain a broader view of the interactions that connect genotypes to phenotypes of interest. Omics data integration can provide a more reliable and holistic picture of the biochemistry and dynamics of biological systems, as compared to data from any omics layer alone. Multi-omics is also a powerful tool for discovery and prioritization of biomarkers, which is a topic of high interest in clinical research. To understand biological processes within the systems biology context, various statistical and computational tools are typically employed in multi-omics studies. In clinical studies, data integration across different omics is a promising tool for the early detection of various diseases, as well as for evaluating the efficacy of different treatments. Therefore, the aim of this Research Topic was to cover advances in the multi-omics research field with consideration of clinical applications. This Research Topic of five articles involves multi-omics studies of different diseases.

By integrating genomics and transcriptomics data, [Wang et al.](#) evaluated the effect of smoking history on cancer patients and proposed a 46-gene model to predict overall survival of the patients, as well as to disease-specific survival and progression-free intervals.

To understand esophageal squamous cell carcinoma (ESCC), [Zang et al.](#) combined comprehensive metabolomic characterization with expression profiling of interleukin enhancer binding factor 2 (ILF2) and ILF3, proteins known to contribute to the occurrence and development of several types of malignancy. The results indicated

that a series of acyl-carnitines were positively correlated with the levels of ILF2 in ESCC tissues and that elevated ILF3 expression in ESCC tissues was negatively correlated with the levels of several key intermediate metabolites in the glycolysis pathway.

The development of malignant gliomas and its relation to lysine acetylation regulators (LARs) were investigated by [Tu et al.](#) through RNA-seq transcriptome data and microarray mRNA expression profile correlated to clinicopathological features. The authors identified three glioma subtypes (LA1, 2, and 3), and proposed a LAR-signature related to tumor mutation burden of the patients which presented strong and independent prognostic value for glioma patients in both training and validation datasets.

Cerebral infarction (CI) was studied by [Chen et al.](#) by performing an untargeted metabolomics approach of serum samples of patients across different CI phases. Metabolic pathway analysis indicated that phenylalanine metabolism was involved in the development of CI within 3–7 days and galactose metabolism, inositol phosphate metabolism, and ascorbate and aldarate metabolism were differentially active only between the CI diabetic patients and healthy control groups.

Finally, [Qin et al.](#) studied right ventricular failure (RVF) in a monocrotaline (MCT)-induced PAH rat model. Proteomic and metabolomic profiles of the RV myocardium were obtained and bioinformatics analysis indicated that elevated intracellular calcium concentrations and inflammation might contribute to myocardial proliferation and contraction, which may be beneficial for maintaining the compensated state of the RV. Ferroptosis, mitochondrial metabolic shift, and insulin resistance are significantly involved in the RVF stage. Dysregulated iron homeostasis, glutathione metabolism, and

lipid peroxidation related to ferroptosis may contribute to RV decompensation.

Most current literature on multi-omics studies comprises the integration of genetic and transcriptomics data. Nevertheless, there is a growing interest in the integration of proteomics and metabolomics with the aim to provide biological information closer to the phenotype, as approached in this Research Topic.

Author contributions

AS: writing and editing; JX and MO: editing and revising the manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.